Coave Therapeutics Presents Non-Human Primate Data Supporting Lead Wet AMD Gene Therapy Program at Euretina 2026

New non-human primate data show Coave's ligand-conjugated suprachoroidal vector, coAAV-SCS, achieved up to 120-fold higher retinal and ...
Yahoo Finance

Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery

PARIS, France – 14 November 2025: Coave Therapeutics ("Coave"), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces the ...
Business Insider

Coave Therapeutics to Present New Data on Wet AMD Gene Therapy Program at 26th Euretina Congress as it Advances towards the Clinic

Dr. Nora Dimon, VP of Clinical Development, to present preclinical findings on the Company’s lead retinal program, CoTx-101, including non-human primate data Rodolphe Clerval, CEO, to deliver a ...
Yahoo Finance

Coave Therapeutics Presents Non-Human Primate Data Supporting Lead Wet AMD Gene Therapy Program at Euretina 2026

PARIS, France – 5 October 2026: Coave Therapeutics ("Coave"), a company redefining ocular gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, announces that it presented ...